CD177 and glioblastoma: Quantitative PCR (qPCR) revealed 32-fold more total FN and 16-fold elevation of the EDA splice variant in CAFs relative to TAMs (P = 0.002–0.004; Figure 5A) and tumor cells (P = 0.002; Figure 5A), suggesting that EDA is a more specific GBM CAF biomarker than the cell-surface receptors described for other CAFs (Supplemental Figure 4 and Supplemental Table 2).